| Literature DB >> 27121955 |
Wen Gao1, Le-bin Song2, Jie Yang3, Ning-hong Song3, Xin-feng Wu4, Ning-jing Song5, Di Qiao6, Chen Chen7, Jia-yi Zhang3, Zeng-jun Wang8.
Abstract
BACKGROUND: Delayed first medical consultation (patient's delay) is quite common in cases of penile carcinoma (PC), but its reasons and impacts remain unclear. We conducted this study to ascertain risk factors resulting in delayed treatment seeking and evaluate its influence on prognosis.Entities:
Keywords: Male sexual function; Overall survival; Patient’s delay; Penile carcinoma; Relapse; Risk factors
Mesh:
Year: 2016 PMID: 27121955 PMCID: PMC4848776 DOI: 10.1186/s12957-016-0863-z
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Flow diagram of patients involved in the study
Fig. 2Distributions of patients’ numbers in time duration of patient’s delay (a), primary subjective reasons for delay (b), and initial symptoms (c)
Multivariate logistic regression models of risk factors for delayed first medical consultation
| Variables | Treatment seeking (%) | Multivariate analysisa | |||
|---|---|---|---|---|---|
| Undelayed ( | Delayed ( | OR (95 % CI) |
| ||
| Marital status | Married | 54 (78.3) | 124 (67.0) | Reference | |
| Cohabitation | 4 (5.8) | 6 (3.2) | 0.439 (0.086–2.239) | 0.322 | |
| Single | 11 (15.9) | 55 (29.7) | 2.372 (1.025–5.490) | 0.044 | |
| Frequency of sexual intercourse/mo | ≥5 times | 15 (21.7) | 26 (14.1) | Reference | |
| 2–4 times | 43 (62.3) | 104 (56.2) | 1.102 (0.452–2.685) | 0.831 | |
| 0–1 time | 11 (15.9) | 55 (29.7) | 2.714 (0.918–8.022) | 0.071 | |
| Education | ≥ Graduate | 13 (18.8) | 21 (11.4) | Reference | |
| Secondary school | 37 (53.6) | 84 (45.4) | 1.238 (0.476–3.224) | 0.662 | |
| ≤ Primary school | 19 (27.5) | 80 (43.2) | 2.053 (0.741–5.687) | 0.167 | |
| Place of residence | City or town | 43 (62.3) | 80 (43.2) | Reference | |
| Rural area | 26 (37.7) | 105 (56.8) | 2.524 (1.276–4.994) | 0.008 | |
| Utilization of Internet | Almost everyday | 19 (27.5) | 38 (20.5) | Reference | |
| Occasionally | 38 (55.1) | 81 (43.8) | 0.553 (0.235–1.304) | 0.176 | |
| Never | 12 (17.4) | 66 (35.7) | 1.866 (0.706–4.931) | 0.208 | |
| Drinking alcohol habit, ml/week | Never or occasionally | 19 (27.5) | 32 (17.3) | Reference | |
| Slight (≤400a) | 43 (62.3) | 119 (64.3) | 1.380 (0.620–3.068) | 0.430 | |
| Heavy (>400) | 7 (10.1) | 34 (18.4) | 3.574 (1.119–11.416) | 0.032 | |
| Family history of cancer | Yes | 21 (30.4) | 34 (18.4) | Reference | |
| None | 48 (69.6) | 151 (81.6) | 1.999 (0.946–4.225) | 0.070 | |
| Initial symptom | Warts or tumors | 18 (26.1) | 33 (17.8) | Reference | |
| Superficial fissure with/without pain | 7 (10.1) | 15 (8.1) | 1.223 (0.366–4.093) | 0.744 | |
| Erythema or eczema with/without pruritus | 12 (17.4) | 54 (29.2) | 3.224 (1.165–8.925) | 0.024 | |
| Ulceration | 15 (21.7) | 30 (16.2) | 0.840 (0.306–2.308) | 0.736 | |
| Induration | 6 (8.7) | 32 (17.3) | 3.592 (1.068–12.084) | 0.039 | |
| Infection | 8 (11.6) | 10 (5.4) | 0.682 (0.181–2.574) | 0.573 | |
| Uncertain or cannot recall | 3 (4.3) | 11 (5.9) | 2.232 (0.481–10.356) | 0.305 | |
| History of STIs | None or uncertain | 34 (49.3) | 116 (62.7) | Reference | |
| Condyloma acuminatum | 15 (21.7) | 20 (10.8) | 0.322 (0.128–0.812) | 0.016 | |
| Gonorrhea | 7 (10.1) | 24 (13.0) | 1.218 (0.420–3.534) | 0.716 | |
| Syphilis | 4 (5.8) | 3 (1.6) | 0.293 (0.048–1.809) | 0.186 | |
| Nongonococcal urethritis | 6 (8.7) | 16 (8.6) | 0.872 (0.249–3.050) | 0.830 | |
| ≥2 STIs | 3 (4.3) | 6 (3.2) | 0.511 (0.091–2.873) | 0.446 | |
STIs sexually transmitted infections, PC penile carcinoma, OR odds ratios, CI confidence intervals
aAdjusted for all covariates in the table
Impacts of diverse delayed extents on lesion characteristics and primary treatment strategies
| Variables | Lesion size, cm (≤2 vs | Primary tumor (Tisb/Ta/T1a vs. T1b–T4) | Lymph nodes (N0 vs | Distant metastasis (M0 vs | Primary strategies (penis-sparingc vs | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| |
| Undelayed ( | Reference | Reference | Reference | Reference | Reference | |||||
| Delay 1–3 months ( | 1.432 (0.679–3.018) | 0.342 | 1.502 (0.616–3.660) | 0.369 | 1.920 (0.609–6.055) | 0.259 | 1.015 (0.986–1.044) | 1.000e | 1.446 (0.543–3.850) | 0.459 |
| Delay 3–6 months ( | 3.294 (1.533–7.077) | 0.002 | 2.950 (1.227–7.092) | 0.013 | 6.400 (2.192–18.689) | <0.001 | 1.059 (0.992–1.130) | 0.082e | 3.530 (1.376–8.891) | 0.007 |
| Delay >6 months ( | 6.424 (2.993–13.787) | <0.001 | 3.726 (1.604–8.656) | 0.002 | 7.549 (2.653–21.483) | <0.001 | 1.107 (1.021–1.201) | 0.010e | 4.497 (1.830–11.052) | 0.001 |
OR odds ratios, CI confidence intervals, Tis carcinoma in situ
aThe integer of average
bPenile carcinoma in situ includes erythroplasia and Bowen’s disease
cPenis-sparing includes penis-sparing surgery, micrographic surgery, and laser ablation or excision
dOthers include partial amputation, total penectomy, and alleviative treatment
eFisher exact test
Impacts of diverse delayed extents on the subjective evaluation of sexual potency at the 6th month end after treatments
| IIEF-15 domains | Erectile function (19–30a vs | Orgasmic function (7–10a vs | Sexual desire (7–10a vs | Intercourse satisfaction (10–15a vs | Overall satisfaction (7–10a vs | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| |
| Undelayed ( | Reference | Reference | Reference | Reference | Reference | |||||
| Delay 1–3 months ( | 1.554 (0.650–3.712) | 0.319 | 1.660 (0.755–3.650) | 0.206 | 1.529 (0.508–4.608) | 0.448 | 1.571 (0.702–3.519) | 0.270 | 1.643 (0.708–3.812) | 0.246 |
| Delay 3–6 months ( | 2.913 (1.151–7.371) | 0.021 | 2.716 (1.135–6.498) | 0.023 | 2.391 (0.756–7.565) | 0.131 | 2.977 (1.233–7.190) | 0.014 | 2.921 (1.177–7.250) | 0.019 |
| Delay >6 months ( | 3.344 (1.358–8.231) | 0.007 | 3.010 (1.288–7.034) | 0.010 | 3.178 (1.067–9.466) | 0.032 | 3.639 (1.541–8.594) | 0.003 | 3.311 (1.368–8.009) | 0.007 |
IIEF International Index of Erectile Function, OR odds ratios, CI confidence interval
aNo or mild dysfunction for each domain of IIEF-15 [8]
Impacts of diverse delayed extents on overall survival and disease relapses
| Variables | Overall survival, year (≥2 vs | Overall survival, year (≥5 vs | Relapses within 2 yearsa (none vs | Relapses within 5 yearsa (none vs | |||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| OR (95 % CI) |
| ||
| Undelayed ( | Reference | Reference | Undelayed ( | Reference | Reference | ||||
| Delay 1–3 months ( | 0.984 (0.134–7.209) | 1.000e | 1.309 (0.456–3.762) | 0.616 | Delay 1–3 months ( | 0.803 (0.307–2.097) | 0.653 | 0.870 (0.395–1.914) | 0.728 |
| Delay 3–6 months ( | 2.905 (0.509–16.587) | 0.238e | 1.684 (0.564–5.034) | 0.347 | Delay 3–6 months ( | 0.709 (0.242–2.081) | 0.530 | 0.694 (0.286–1.689) | 0.420 |
| Delay >6 months ( | 5.191 (1.053–25.598) | 0.043e | 2.476 (0.909–6.746) | 0.070 | Delay >6 months ( | 0.945 (0.359–2.487) | 0.909 | 0.714 (0.307–1.659) | 0.433 |
OR odds ratios, CI confidence intervals
aAfter radical therapies
bRelapses includes local, regional, and distant recurrences, and new primary lesions are classified into local recurrence
eFisher exact test